Scarica l'app Stockscreener
39.49
6.76%
2.50
Pre-mercato:
50.72
11.23
+28.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Why Is SLNO Stock Surging Over 20% Overnight? - Stocktwits
Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT (NBIX:NASDAQ) - Seeking Alpha
Neurocrine nears $2.5 billion deal for Soleno Therapeutics, FT reports - marketscreener.com
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Do Ongoing DCCR Lawsuits Reframe Soleno Therapeutics’ (SLNO) Risk Profile More Than Its Drug Potential? - simplywall.st
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - PR Newswire
Soleno Therapeutics Faces Lawsuit After DCCR Launch Setback and Share Drop - National Today
SLNO INVESTOR ALERT: Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman - ChartMill
Soleno Therapeutics Investors Eligible to Lead Securities Fraud Lawsuit - National Today
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - GlobeNewswire Inc.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - ACCESS Newswire
Banque Pictet & Cie SA Takes $2.03 Million Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
H.C. Wainwright cuts Soleno Therapeutics stock price target to $100 - Investing.com
Soleno Therapeutics Faces Class Action Lawsuit Over Drug Trial Concerns - National Today
Class Action Lawsuit Filed Against Soleno Therapeutics Over DCCR Disclosures - Intellectia AI
Soleno Therapeutics, Inc. (SLNO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Soleno Therapeutics (SLNO) Faces Securities Class Action - GlobeNewswire
Soleno Therapeutics, Inc. Class Action Lawsuit: Investors Face May 5, 2026, Deadline - PR Newswire
Soleno Therapeutics Inc (6XC.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno ... - Bluefield Daily Telegraph
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
Soleno Therapeutics’ (SLNO) Investor Sentiment Subdued Amid Growth Concerns - Insider Monkey
SLNO Stock Price, Quote & Chart | SOLENO THERAPEUTICS INC (NASDAQ:SLNO) - ChartMill
Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman - Sahm
REMINDER: Soleno Therapeutics, Inc. Investors With - GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud - GuruFocus
(SLNO) Volatility Zones as Tactical Triggers - Stock Traders Daily
SLNO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors ... - bdtonline.com
SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky - Morningstar
Soleno Therapeutics (SLNO) Still Appears Attractive Despite Slower U.S. Launch Ramp Projections - Insider Monkey
SLNO PE Ratio & Valuation, Is SLNO Overvalued - Intellectia AI
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Soleno Therapeutics: Huang sells $200k in shares By Investing.com - Investing.com South Africa
Soleno (NASDAQ: SLNO) SVP sells 6,582 shares to cover RSU tax obligations - Stock Titan
Soleno Therapeutics: Huang sells $200k in shares - Investing.com
Soleno Therapeutics Investors Seek Compensation After Losses - National Today
SLNO Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Soleno Therapeutics (SLNO) Falls Hard on Patient Death - msn.com
Soleno Therapeutics (NASDAQ:SLNO) Stock Price Up 10%Time to Buy? - MarketBeat
Investors Purchase Large Volume of Soleno Therapeutics Call Options (NASDAQ:SLNO) - MarketBeat
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO) - TMX Newsfile
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Cla - GuruFocus
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):